Eisai wins kidney cancer approval as Eisai stock trades 7.82 percent below its 52-week high

Published on 10/01/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eisai stock costs EUR 26.84 on October 1, 2026 versus EUR 27.10. First-quarter revenue reached JPY 234.33 billion and earnings JPY 18.24 billion.

Eisai, JP3160400002, Illustration mit AI erstellt.

Eisai (JP3160400002) was trading at EUR 26.84 at Lang & Schwarz on October 1, 2026, minus 0.96 percent versus the prior close of EUR 27.10. The company received U.S. approval for WELIREG plus LENVIMA on September 28, 2026, while its Tokyo-listed stock stood 7.82 percent below its JPY 5,243.00 52-week high.

Kidney cancer approval broadens growth

According to Eisai on September 28, 2026, the U.S. Food and Drug Administration approved WELIREG, or belzutifan, combined with LENVIMA, or lenvatinib, for certain previously treated adults with advanced renal cell carcinoma with a clear cell component.

The approval is based on the Phase 3 LITESPARK-011 trial, which compared the combination with cabozantinib after treatment with a PD-1 or PD-L1 inhibitor. For Eisai, the decision adds an oncology catalyst alongside the company's Alzheimer's disease franchise and gives LENVIMA another commercial use with Merck's WELIREG.

First-quarter figures set the test

Yahoo Finance reports that Eisai generated JPY 234.33 billion of revenue and JPY 18.24 billion of earnings in the first quarter of fiscal 2027, ended June 30, 2026. Earnings per share reached JPY 64.71 in that period.

The operating picture also matters because the first-quarter revenue figure accounts for 26.52 percent of the JPY 883.50 billion full-year revenue outlook reported for fiscal 2027. That comparison puts the September approval into a measurable earnings framework: commercial execution must convert the expanding product access into additional revenue during the remaining fiscal year.

Stock remains below its yearly high

On the Tokyo Stock Exchange, Eisai was last quoted at JPY 4,833.00 on October 1, 2026 at 3:30 p.m. JST, down JPY 22.00 from the prior close of JPY 4,855.00. The JPY 3,660.00 to JPY 5,243.00 52-week range places the stock 7.82 percent below its high.

Yahoo Finance lists November 10, 2026 as Eisai's next earnings date. That report will provide the next quantified test of revenue progress after the first-quarter JPY 234.33 billion result.

October price snapshot

Eisai was trading at EUR 26.84 at Lang & Schwarz on October 1, 2026 at 12:12 p.m. CEST, minus 0.96 percent versus the Lang & Schwarz prior close of EUR 27.10 on September 30, 2026.